Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"with one patient now entering the eleventh month of therapy"
Holy Shitballs! Might be better than the spleen lesion disappearing...
TD, it is in the yahoo news feed.
I read the old alert that sox posted, and sent an email to: whistleblower@finra.org
I suggest others do the same.
Thank you for your insights. Also, how nice it is to talk about science on this board.
HA! I think hell might have officially frozen over because I want to say the catalyst is GeorgiePorgie's pump!
I think gov has been making her rounds, holding up signs and trying to convince people on the street to join the trial. She also peeks in Leo's living room window to try and read his laptop.
Couldn't resist, huh?
Should definitely put to rest the R/S talk at a minimum...
Thanks for sharing!
Just as a precaution, I'm buckling up my seat belt.
I am. Thought the same thing.
Poorly phrased. I was merely trying to say that the numbers you posted exceeded my expectations (in a good way) on how little this next phase would cost.
Those figures would be awesome (even the $10 million). I was hoping the orphan drug designation would keep a lid on the figure.
And to piggy back on your question, I wonder what the cost of a phase 2/3 for ovarian cancer will be and if this is something CTIX will try and try to finance through Aspire/shelf/dilution path or if they are currently seeking a partner for this trial...any thoughts welcome...
Perfectly stated. Thanks, Sox. B-OM is a big deal for MANY reasons.
One of my guesses is: Leo wants to wait on the corporate update until the P trial has started. I have a hard time seeing him give us a corporate update that says: P trial to start "this week" or "soon". If it starts on Tuesday, I expect the update to come for Wednesday, July 29th*
* I attach approximately 15% chance of all of the above happening
Hey, cursing is fine, but please don't use THAT word...
Nice catch, sox. The news will just keep coming!
Awesome find, ericeb2003! To the moon!
Thank you, LR!
Thanks for this. Leo is continuing to deliver...
Good find. Thanks for posting.
Thanks for asking these questions and posting his response. Much appreciated.
5400 volume last 2.55 Scottrade
I have 10:31a
Wow, those numbers are a lot higher than I thought...
Agreed. Interestingly they only took 1 gynecological cancer patient for cohort 9* (which we refer to as cohort 10 @ 450 mg) and the first patient in cohort 10 (which we refer to as 11 @ 750/mg) was for a lung cancer. Hope they are now targeting other cancers.
*added this because DF refers to cohort 1 as 0. All other cohorts on their posters are one less than we refer to them as...
Hi Ffrol,
From the Jan. presentation:
Kevetrin - Study CTIX-0000
One Subject’s Experience
•57 year-old female with metastatic ovarian carcinoma (lesions in colon, spleen)
and ascites requiring weekly paracentesis
•Kevetrin begun 1 Oct 2014 at 350 mg/m2 once weekly
•Cycle 1 (1-22 Oct) – Subject reported increased energy--
went hiking with her family
•Cycle 2 (29 Oct – 21 Nov) – Scans repeated -- ascites decreased, previous
noted splenic lesion nearly completely absent, CA 125 stable, lower
volume of ascitic fluid on paracentesis
•Cycle 3 (25 Nov-17 Dec) – Scans repeated -- stable since end of Cycle 2,
CA 125 result was increased by ˜ 10%, subject chose to withdraw from
the study in consultation with her oncologist
Thanks for this correction, I was getting confused by one the other conditions we are going to cure - "ulcerative proctitis". That is what I meant would be referred to as a PIA.
Pain in the ass or PIA for short.
And, ASCO ends tomorrow at 12:45 pm. Based on his wording, we might get that update before the end of the day...
http://am.asco.org/tuesday-june-2-2015
I might be a dummy, but I'm no idiot...
Another dummy here. Count me in.
Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
BEVERLY, MA--(Marketwired - June 01, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that last week a second site opened enrollment in the Company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemoradiation. Clinical sites in Oregon and South Dakota are now enrolling patients to evaluate Brilacidin-OM for efficacy with additional sites to be added in June to keep the trial progressing in a timely manner.
More information on the trial can be found at https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=2.
Besides targeting the huge unmet medical need for an effective therapeutic for oral mucositis, the Brilacidin-OM trial has significant implications for Cellceutix shareholders. Should the anti-inflammatory properties of Brilacidin-OM work in the trial as anticipated, Cellceutix will immediately turn its attention to inflammatory diseases, such as hidradenitis suppurativa (HS) and gastrointestinal diseases, as planned. Cellceutix believes the potential market size for its defensin mimetics as anti-inflammatory compounds is even greater than the substantial market for antibiotic applications.
"We expect this trial of Brilacidin-OM to move efficiently and are very pleased to see another clinical site already open for enrolling patients," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "As this trial is underway we are completing the formulation work for treating hidradenitis suppurativa. Actually, the timing couldn't be better with the U.S. Food and Drug Administration recently granting AbbVie an orphan drug designation for HUMIRA® (adalimumab) for the investigational treatment of moderate-to-severe HS. The designation answered many questions for us and is certainly something we will apply for as well in order to try and shave millions of dollars and years off the clinical trials."
Cellceutix will be issuing a separate update on the events at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting shortly after its conclusion on Tuesday, June 2, 2015.
Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.VNkn7FY9.dpbs.
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix has begun a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Contact:
INVESTOR AND MEDIA CONTACT:
Cellceutix Corporation
Leo Ehrlich
Email contact
Thank you for this explanation.
Don't you have through tomorrow?
New Article, I haven't even read it yet...
http://ir.baystreet.ca/article.aspx?id=132&1432818006
Not the answer I was hoping for, but for those who were wondering if there was more flexibility for the Russell index...
My question: "I am following a company that is uplisting to the NASDAQ exchange and expect the market cap to make them eligible for the Russell 2000 index. If they have not been accepted by NASDAQ by Friday (May 29), will they be excluded from this year's index reconstitution? Is there any flexibility for companies uplisting in early June?"
Answer: "Thank you for contacting Russell Indexes. A stock must be listed and trading on NASDAQ or NYSE at $1 or more on the last trading day in May to be eligible, along with our other eligibility rules.
The first few pages of our methodology document has information on our inclusion criteria.
Let me know if you have further questions.
Thanks,
Jessica Wu
Client Service Associate | Russell Indexes
p: 212-702-7975 | jwu@russell.com"
Wrong person?